Delving into the Latest Updates on China National Pharmaceutical Industry Corp. Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Nervous System Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

Cav2.1(calcium voltage-gated channel subunit alpha1 A)	1
COX x Opioid receptors	1
adrenergic receptor(Adrenergic receptors)	1

主要研究目的：以国药集团工业有限公司研制的培哚普利吲达帕胺片（规格：培哚普利叔丁胺盐4 mg，吲达帕胺1.25 mg）为受试制剂，按生物等效性研究的有关规定，与施维雅（天津）制药有限公司生产的培哚普利吲达帕胺片（参比制剂，商品名：百普乐®，规格：培哚普利叔丁胺盐4 mg，吲达帕胺1.25 mg）对比在健康人体内的相对生物利用度，考察两制剂的人体生物等效性。次要研究目的：观察培哚普利吲达帕胺片受试制剂和参比制剂（规格：培哚普利叔丁胺盐4 mg，吲达帕胺1.25 mg）在健康受试者中的安全性。

[Translation]

Main research purpose: Using the perindopril indapamide tablets (specifications: perindopril tert-butylamine salt 4 mg, indapamide 1.25 mg) developed by Sinopharm Group Industrial Co., Ltd. as the test preparation, according to the relevant provisions of bioequivalence studies, the relative bioavailability in healthy humans was compared with the perindopril indapamide tablets (reference preparation, trade name: Bipro®, specifications: perindopril tert-butylamine salt 4 mg, indapamide 1.25 mg) produced by Servier (Tianjin) Pharmaceutical Co., Ltd., to investigate the human bioequivalence of the two preparations. Secondary research purpose: Observe the safety of the test preparation and reference preparation of perindopril indapamide tablets (specifications: perindopril tert-butylamine salt 4 mg, indapamide 1.25 mg) in healthy subjects.

Start Date04 Aug 2023

Sponsor / Collaborator

China National Pharmaceutical Industry Corp. Ltd.

CTR20230488 / CompletedNot Applicable

评价富马酸喹硫平缓释片在中国健康受试者中空腹和餐后状态下的开放、随机、单次给药生物等效性试验

[Translation] An open-label, randomized, single-dose bioequivalence study to evaluate the fasting and fed state of quetiapine fumarate extended-release tablets in healthy Chinese subjects

主要目的：以国药集团工业有限公司生产的富马酸喹硫平缓释片（规格：200mg）作为受试制剂，AstraZeneca Pharmaceuticals LP生产的富马酸喹硫平缓释片（规格：200mg）作为参比制剂，评价受试制剂与参比制剂在健康受试者空腹和餐后状态下的生物等效性。次要目的：评价中国健康成年受试者口服受试制剂、参比制剂后的安全性。

[Translation]

Primary objective: Quetiapine fumarate sustained-release tablets (specification: 200 mg) produced by Sinopharm Group Industrial Co., Ltd. were used as the test preparation, and quetiapine fumarate sustained-release tablets (specification: 200 mg) produced by AstraZeneca Pharmaceuticals LP were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects in the fasting and fed state. Secondary objective: Evaluate the safety of the test preparation and the reference preparation after oral administration in healthy Chinese adult subjects.

Start Date18 Mar 2023

Sponsor / Collaborator

China National Pharmaceutical Industry Corp. Ltd.

CTR20222818 / TerminatedNot Applicable

评价富马酸喹硫平缓释片在中国健康受试者开放、随机、单次给药的空腹和餐后状态的生物等效性试验

[Translation] An open-label, randomized, single-dose bioequivalence study to evaluate the fasting and fed status of quetiapine fumarate extended-release tablets in healthy Chinese subjects

主要目的以国药集团工业有限公司生产的富马酸喹硫平缓释片（规格∶200mg）作为受试制剂，AstraZeneca Pharmaceuticals LP生产的富马酸喹硫平缓释片（规格∶200mg）作为参比制剂，评价受试制剂与参比制剂在健康受试者空腹和餐后状态下的生物等效性。次要目的∶ 评价中国健康成年受试者口服受试制剂、参比制剂后的安全性。

[Translation]

Main purpose Quetiapine fumarate sustained-release tablets (specification: 200 mg) produced by Sinopharm Group Industrial Co., Ltd. were used as the test preparation, and quetiapine fumarate sustained-release tablets (specification: 200 mg) produced by AstraZeneca Pharmaceuticals LP were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects in the fasting and fed state. Secondary purpose: Evaluate the safety of the test preparation and the reference preparation after oral administration in healthy adult Chinese subjects.

Start Date26 Nov 2022

Sponsor / Collaborator

China National Pharmaceutical Industry Corp. Ltd.

100 Clinical Results associated with China National Pharmaceutical Industry Corp. Ltd.

Login to view more data

0 Patents (Medical) associated with China National Pharmaceutical Industry Corp. Ltd.

Login to view more data

1

Literatures (Medical) associated with China National Pharmaceutical Industry Corp. Ltd.

Huagong Sheji Tongxun

Study on extraction of flavonoids of centella asiatica by microwave-assisted method

Author: Zhao, Yue-feng

Objective: To study the effect of microwave-assisted extraction of flavonoids from Centella asiatica.Method: Choose the Centella asiatica material, use hot air drying, natural air drying and microwave assisted methods to determine the drying effect and the extraction efficiency of flavonoids.Results: In the microwave drying method, the microwave power was 406W, the time was 90s, the ethanol concentration was 70%, the solid-liquid ratio was 1:20, and the effect of extracting the flavonoids from Centella asiatica was the best.Conclusion: The microwave-assisted method can more effectively dry Centella asiatica and successfully extract the flavonoids.

100 Deals associated with China National Pharmaceutical Industry Corp. Ltd.

Login to view more data

100 Translational Medicine associated with China National Pharmaceutical Industry Corp. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

2

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Compound Bismuth Subgallate Suppositories II ( adrenergic receptor )	Hemorrhoids More	Approved
Ibuprofen/Codeine Phosphate ( COX x Opioid receptors )	-	Approved
Nifedipine ( Cav2.1 )	-	Phase 1
Omeprazole ( Proton pump )	Gastrinoma More	Pending